Waters Unveils New Technologies for Food Safety, Food Authenticity and Biomedical Research at ASMS 2018
Waters demonstrates the power and potential of mass spectrometry by showcasing new technologies
Waters demonstrates the power and potential of mass spectrometry by showcasing new technologies
Rigaku NEX LS scanner performs multi-element composition, coat weight and coating thickness analyses for web and coil applications
Ncardia develops, produces and commercializes highly predictive human cellular assay systems for safety and efficacy testing. The product portfolio encompasses a broad panel of hiPSC derived cryopreserved cardiomyocytes and neurons. In addition, the company delivers the CardioPlateTM product line of quality controlled ready to use assay plates. Using its cell products, Ncardia develops and provides its customers with a broad portfolio of cardiovascular services from safety pharmacology and disease modeling to cardiovascular drug efficacy screening. Ncardia is based in Belgium, The Netherlands, Germany, and the USA. The company is privately held and was established in September 2017 following the merger of Pluriomics and Axiogenesis, two well-known pioneers in the field of stem cell derived cells for safety and toxicology assessment.
A best-in-class DNA transfection reagent for your research.